KEY INVESTOR MESSAGES
- Faster than expected development of the second immuno-oncology (I-O) program, a LAG3 inhibitor, allows company to evolve its lead program into a more ambitious LAG3/PD-L1 bispecific aiming to enter the clinic in 2020
- Good progress of the ongoing external collaborations in two key areas: gene delivery (Moderna, OncoSec, FIT Biotech) and drug conjugates (Glythera)
- Expect further licensing deals for Affimer reagents, based on multiple on-going evaluations
- Stock price weakness reflects in our view uncertainty around a likely capital raise before year end rather than the company's strong fundamentals
We have updated our chart showing key milestones expected in the near term for the numerous in-house and external programs.
The initial research phase of the collaboration with Moderna has a natural end point in May 2018; we expect Avacta to potentially announce an extension of this collaboration in the next couple of months or to have transferred an Affimer to Moderna for them to develop.